The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Open accessAbstract
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette–Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis. Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistent M. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB. This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Tumor necrosis factor signaling
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,359
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationFlynn, J. L., & Chan, J. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.93 · Cited by 2,155
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677
Cited by
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Metadata
- Authors
- Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., Schölvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., Bossink, A., Duarte, R., Erkens, C., Clark, J., Migliori, G. B., & Lange, C.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2010-06-07
- Volume
- 36
- Issue
- 5
- Pages
- 1185-1206
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2097362715
- Cited by
- 527
- References
- 131
- FWCI
- 25.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. https://app.cochat.ai/papers/10.1183/09031936.00028510
- The paper
- Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., Schölvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., . . . Lange, C. (2010). The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal. https://doi.org/10.1183/09031936.00028510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
